Jul 25th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Futibatinib (brand name: Lytgobi) is an FDA-approved medication used to treat certain types of bile duct cancer (cholangiocarcinoma).

STADA and Alvotech introduce Uzpruvo, the initial ustekinumab biosimilar approved against Stelara, in Europe.

Gadopiclenol, known by its brand names Elucirem, Vueway, and Elucirem Prefilled Syringe, was approved by the FDA on September 21, 2022.

Gan & Lee Pharmaceuticals' GZR18 injection, a bi-weekly GLP-1 receptor agonist, showed a 17.29% weight reduction after 30 weeks in a Phase IIb study.

Terlipressin, marketed under the brand name Terlivaz, was approved by the FDA on September 14, 2022.

Jul 24th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Deucravacitinib, marketed under the brand name Sotyktu, was approved by the FDA on September 9, 2022.

Nuvalent reported the launch of HEROEX-1, its Phase 1a/1b clinical study testing the new HER2-selective inhibitor NVL-330.

Daxxify, with the generic name daxibotulinumtoxinA-lanm, is an FDA-approved medication used for both cosmetic and therapeutic purposes.

Johnson & Johnson is requesting U.S. FDA approval for SPRAVATO® (esketamine) as the sole treatment for adults with treatment-resistant depression.

Spesolimab, marketed under the brand name Spevigo, received FDA approval for the treatment of generalized pustular psoriasis flares in adults.